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The effect of formulation variables on in-vitro release and permeation properties of carve-
dilol from transdermal patch was studied by varying one factor at a time as preliminary
study. Based on these results, design of experiments technique was applied followed by
regression analysis and response surface methodology to optimize formulation variables.
Central Composite IV model design was used with four formulation variables: drug loading,
matrix thickness, adhesive layer thickness, and propylene glycol concentration. Nineteen
formulations were prepared according to the design; and the effect of formulation variables
was studied on in-vitro release and permeation profiles of these formulations. In all cases,
the permeation profiles paralleled in-vitro release profiles. The drug released at 7 h and 24 h
was used as release response parameters while permeation flux obtained was employed as
permeation response parameter. All four formulation variables were found to be significant
for release properties and three of these exhibited significant effect on permeation profile of
carvedilol across artificial membrane. Constrained optimization, using 47.9% of cumulative
carvedilol released at 7 h and 99.8% at 24 h as well as 25.7 mg/cm2/h of permeation flux, was
applied to obtain desired release and permeation profiles. Experimentally, carvedilol was
observed to release from the optimized formulation with 51.4% drug release at 7 h and 98.5%
at 24 h with an observed flux value of 27.4 mg/cm2/h across artificial membrane, which
showed an excellent agreement with the predicted values. The results of this investigation
show that the quadratic mathematical model developed could be used to further predict
formulations with desirable release and permeation properties.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.; fax: þ1 (718) 990 1877.
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a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 8e3 8 291. Introduction 2. Materials and methodsCarvedilol is a potent beta-adrenergic blocking agent
commonly used in hypertension, left-ventricular dysfunction,
and several other cardio-vascular disorders. Currently, car-
vedilol is administered orally in the form of tablets. The rec-
ommended dose for carvedilol is 3.125e6.25mg twice a day for
7e14 days for hypertension, left-ventricular dysfunction or
following myocardial infarction. Although carvedilol is
completely absorbed from the gastrointestinal tract after
ingestion of traditional peroral tablets, the systemic avail-
ability is only about 25%. This leads to several dose-related
side effects, such as bradycardia, cardiac insufficiency,
cardiogenic shock and cardiac arrest. Several attempts have
been made to resolve the above mentioned disadvantages,
including development ofmonolithicmatrices of carvedilol by
supercritical fluid, carvedilolecyclodextrin complex, and
buccal sprays of oral suspension [1e3].
The biological properties of carvedilol, such as high first-
pass metabolism and low therapeutic dose, and its suit-
ability for patients requiring long-term treatment and re-
petitive dosing, make carvedilol an interesting candidate for
transdermal administration. Furthermore, the high lip-
ophilicity (log P ¼ 3.97) and low molecular weight (MW 406.5)
also indicate a good probability of carvedilol crossing the
lipophilic skin barrier [4]. Therefore, it should be possible to
control release of carvedilol over a long period of time
thereby decreasing frequency of administration and
improving patient compliance which could prove beneficial
to the patient.
Thus, the objective of this investigation was to develop a
transdermal drug delivery system to deliver carvedilol at a
controlled rate as well as to evaluate formulation variables
which affect in-vitro release and permeation profiles of car-
vedilol. A matrix type design was selected for this investiga-
tion due to its ease of manufacturing and high tensile
strength. Also, it has been reported that a high release or flux
of a lipophilic drug could be obtained if the drug is loaded in a
hydrophilic matrix [5]. Therefore, hydroxypropyl methylcel-
lulose (HPMC) was selected as the matrix polymer. Propylene
glycol was used as the permeation enhancer and a commonly
used polyacrylate was employed as the adhesive.
As a preliminary study, the influence of four formulation
factors (drug loading, matrix thickness, adhesive layer thick-
ness, and propylene glycol concentration) was investigated on
the release and permeation properties of carvedilol from
transdermal patches by changing one factor at a time. After
completion of the preliminary study, an attempt was made to
obtain an optimized formulation by design of experiments so
as to achieve a desired release (50% in 7 h and 100% in 24 h)
and permeation flux (25.7 mg/cm2/h) of carvedilol from the
patch over a particular period of application time of the patch.
The advantages of using this experimental design method in
contrast to the one-factor-at-a-time classic experimental
approach include the following: reduction in the number of
experiments that need to be carried out, identification of
interaction between formulation factors, detection of optimal
response within the experimental region, and empirical
modeling of the data.2.1. Materials
Carvedilol was obtained as free sample from Caraco Phar-
maceuticals (Detroit, MI, USA). Polyester backing membrane
(3M Scotchpak 9733 backing) and release liner (3M
Scotchpak 1020 release liner) were obtained as free samples
from 3M (St. Paul, MN, USA). Propylene glycol, hydroxypropyl
methylcellulose (HPMC) and phosphate buffer solution (pH
6.8) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
The solvents and agents used for the determination of car-
vedilol content in the samples by HPLC method were HPLC
grade and obtained from VWR International (West Chester,
PA, USA). The adhesive (Duro-tak 87-2516) used for this
study was obtained as a free sample from The National
Starch and Chemical Company (Bridgewater, NJ, USA). The
transdermal patch retainer used for the in-vitro release study
was purchased from Quality Lab Accessories (Bridgewater,
NJ, USA). The artificial membrane (MF-Millipore membrane
filter, filter code VSWP) used for the in-vitro permeation study
was purchased from Millipore Corporation (Bedford, MA,
USA).2.2. Analysis of carvedilol
The concentration of carvedilol in the samples was analyzed
using HPLC method (HP1100 series, Agilent Technologies,
Wilmington, DE) with a Symmetry C18 column (5.0 mm,
4.6  250 mm). The mobile phase consisted of methanol,
0.33 N phosphate buffer (4.5 g KH2PO4 and 0.61 g K2HPO4 dis-
solved in 1000 mL purified water), and glacial acetic acid at a
ratio of 60:40:0.3 (by volume) and the flow rate was 1 mL/min
[6]. Carvedilol was detected at 284 nmwith a retention time of
4.7 min. The volume of drug solution injected was 10 mL for
both, standards and samples. The concentration of carvedilol
was quantified by the peak area method from the associated
calibration curve.2.3. Fabrication of carvedilol-loaded transdermal
systems
Solvent casting method was used to prepare transdermal
systems. Briefly, carvedilol was added as an alcoholic solution
to facilitate incorporation of carvedilol into the 2% w/v
aqueous solution of HPMC. Propylene glycol was then added
and the solution was mixed well. Films of required thick-
nesseswere cast on a polyester backingmembrane using a bar
film applicator (Byk Gardner, Columbia, MD, USA) of required
clearance (in unit of micrometers). For instance, a 400 mm of
HPMC matrix thickness was obtained by using a bar film
applicator for 400 mm clearance and so on for other thickness
values. Adhesive layer of required thicknesses was then
applied, after drying the films in an oven at 40 C for 2 h to
evaporate any solvents used, using the same method for
thickness of HPMC matrix. Films of desired size were
sectioned using sharp blade and release liner was then
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loaded transdermal systems were then stored in a desiccator
until further use.2.4. Preliminary study
Transdermal patches having 800 mm matrix thickness, 25 mm
adhesive layer thickness, and 2.5% propylene glycol concen-
tration were prepared with varying carvedilol drug loading
concentrations at 8%, 10%, 12.5% and 15% levels to study the
effect of carvedilol loading in the HPMC-matrix on the release
and permeation profiles of carvedilol. The effect of matrix
thickness (400 mm, 800 mm, and 1600 mm) was studied on car-
vedilol release as well as permeation from the patches in
which carvedilol loading, adhesive layer thickness, and pro-
pylene glycol concentrationwere kept constant at 12.5% of the
polymer, 25 mm, and 2.5%, respectively. Adhesive layer having
a thickness of 12.5 mm, 25 mm, 50 mm, or 100 mmwas applied on
different matrices and carvedilol release as well as perme-
ation was studied while carvedilol loading, matrix thickness,
and propylene glycol concentration were kept constant at
12.5% of the polymer, 800 mm, and 2.5%, respectively. The ef-
fect of various propylene glycol concentrations (1.5%, 2.5%,
3.5%, and 4.5%) was studied on carvedilol release and
permeation from the patches keeping the other values of
carvedilol loading, matrix thickness, and adhesive layer
thickness constant at 12.5% of the polymer, 800 mm, and
25 mm, respectively. The composition of formulations used in
the preliminary study is displayed in Table 1.Table 1 e Composition of formulations generated from prelim
from in-vitro release as well as permeation profiles of respecti
Formulation
code
Formation variable
Carvedilol
loading
(% w/w of
polymer)
HPMC
matrix
thickness
(mm)
Adhesive
layer
thickness
(mm)
Prop
gl
conce
(% v
solu
Effect of carvedilol loading
P1 8 800 25
P2 10 800 25
P3 12.5 800 25
P4 15 800 25
Effect of HPMC matrix thickness
P5 12.5 400 0
P6 12.5 800 0
P7 12.5 1600 0
Effect of adhesive layer thickness
P8 12.5 800 0
P9 12.5 800 12.5
P10 12.5 800 25
P11 12.5 800 50
P12 12.5 800 100
Effect propylene glycol concentration
P13 12.5 800 25
P14 12.5 800 25
P15 12.5 800 25
P16 12.5 800 252.5. Statistical optimization of the formulation variables
using experimental design approach
Following the preliminary study, further evaluation of the
four formulation variables was performed using the principle
of design of experiments to identify an optimal combination
of formulation variables for the fabrication of patches having
desired drug release rate and permeation flux. A Central
Composite IV model of Fusion Pro Software (S-matrix Cor-
poration, Eureka, CA, USA) was selected which consisted of 8
full factorial design points, 8 axial points and 3 center points
(Table 2). This design involved three dependent variables (Y1,
Y2, and Y3) and four independent variables (X1, X2, X3, and X4).
The response surface can be expressed as Y ¼ f(X1, X2, X3, X4).
The four independent variables selected for this study were
X1, carvedilol loading; X2, matrix thickness; X3, adhesive layer
thickness; and X4, propylene glycol concentration in the
patches. All other formulation and processing parameters
were kept invariant throughout the study. The three depen-
dent variables included the following: Y1, carvedilol released
at 7 h; Y2, carvedilol released at 24 h; and Y3, permeation flux
of carvedilol across artificial membrane. The composition of
19 patch formulations based on this model is displayed in
Table 3 which was used for the fabrication of carvedilol-
loaded transdermal systems. Upon the completion of statis-
tical optimization experiments, regression equations and 3-
dimensional response surface plots were generated to study
the contributions of these variables to different response
parameters in order to identify the optimized carvedilol-
loaded transdermal system. The optimized system thusinary studies and results of response parameters obtained
ve formulation of transdermal systems.
Response parameter
ylene
ycol
ntration
/v of
tion)
Cumulative
carvedilol
released
at 7 h
(%  S.D.)
Cumulative
carvedilol
released
at 24 h
(%  S.D.)
Permeation
flux
(mg/cm2/h  S.D.)
2.5 21.9  0.8 32.7  2.4 4.2  0.3
2.5 32.5  4.3 52.8  5.9 11.0  1.0
2.5 45.0  2.9 92.4  5.3 23.5  1.5
2.5 53.4  3.2 100.7  7.3 27.2  2.9
2.5 95.0  1.1 100.1  1.9 115.5  9.3
2.5 90.7  2.7 98.8  3.0 68.9  5.2
2.5 84.3  3.5 96.7  2.7 45.1  5.0
2.5 90.7  2.7 98.8  3.0 68.9  5.2
2.5 79.8  3.1 96.8  4.4 53.9  4.2
2.5 43.8  2.9 92.2  3.8 21.0  3.2
2.5 19.8  0.9 27.9  1.1 4.4  0.2
2.5 17.1  1.0 22.1  1.7 1.8  0.1
1.5 27.9  2.0 42.6  3.5 8.8  3.2
2.5 39.9  1.8 76.4  2.9 17.4  0.9
3.5 48.0  0.8 97.0  5.6 25.8  1.5
4.5 64.5  3.0 102.5  6.3 41.7  2.8
Table 2 e A Central Composite IV model.
Formulation code X1 X2 X3 X4
Factorial points
F1 1 1 1 1
F2 1 1 þ1 þ1
F3 1 þ1 1 þ1
F4 1 þ1 þ1 1
F5 þ1 1 1 þ1
F6 þ1 1 þ1 1
F7 þ1 þ1 1 1
F8 þ1 þ1 þ1 þ1
Axial points
F9 2 0 0 0
F10 þ2 0 0 0
F11 0 2 0 0
F12 0 þ2 0 0
F13 0 0 2 0
F14 0 0 þ2 0
F15 0 0 0 2
F16 0 0 0 þ2
Center points (replicates)
F17 0 0 0 0
F18 0 0 0 0
F19 0 0 0 0
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tistical optimization design.
2.6. In-vitro drug release studies
In-vitro drug release studies from carvedilol-loaded trans-
dermal systems were conducted using USP Apparatus 5,
paddle over disk method, (Distek Evolution 6100 Dissolution
System, North Brunswick, NJ, USA). The transdermal patch
retainer used consisted of 25 cm2 patch placed between a 17-
mesh screen and a glass evaporating dish, clipped together
using plastic clips. The dissolution medium (600 mL) was
phosphate buffer solution (pH 6.8) maintained at a tempera-
ture of 32 0.5 C (corresponding to skin temperature) and the
paddle speed was 50 rpm. Aliquots (1 mL each) were collected
at predetermined interval for 24 h and assayed for carvedilol
concentration using HPLC method described above. Each
release study was performed in triplicate.
2.7. In-vitro permeation studies
The main purpose of in-vitro permeation studies was to
further screen the formulations and to correlate permeation
pattern of carvedilol from the carvedilol-loaded transdermal
systems with the observed release patterns. It has been re-
ported that carvedilol diffuses transdermally mainly by pas-
sive diffusion [4]. An artificial membrane was used instead of
animal skin or human skin in this investigation since the
main purpose was initial screening of the formulations. Also,
it has been reported that the permeation profile through a
mixed cellulose acetate-cellulose nitrate artificial membrane
(MF-Millipore membrane filter, filter code VSWP) could be
correlated with permeation through human skin [7] Hence,
this membrane was selected for the in-vitro permeation study
in this investigation. The membrane was hydrated overnight
in phosphate buffer solution and then placed over thereceptor compartment of Franz diffusion cell with a diffusion
area of 0.64 cm2 and a receptor compartment capacity of
11.5 mL. The carvedilol-loaded transdermal system was
placed over the membrane and sealed with parafilm. The
medium used in the receptor compartment was phosphate
buffer solution, which was maintained at 32  0.5 C by
circulating water jackets. Samples (0.5 mL each) were with-
drawn from the receptor compartment at predetermined in-
tervals and replaced with an equal volume of fresh phosphate
buffer solution to maintain sink conditions. The carvedilol
content of the withdrawn samples was determined by HPLC
method. Each experiment was performed in triplicate. The
cumulative amount of carvedilol permeated per unit area
from the transdermal system through the artificial membrane
into the receptor compartment medium was plotted as a
function of time, and the slope of the linear portion of the plot
was estimated as steady state flux.2.8. Regression analysis of the optimization of
formulation
The contribution of different formulation variables was
compared using analysis of variance (ANOVA) and the level of
significance was taken as P <0.05. Regression analysis was
carried out to obtain a quadratic model in the form shown in
Equation (1):
Y ¼ b0 þ b1X1 þ b2X2 þ b3X3 þ b4X4 þ b5Eþ b6Curvature (1)
In Equation (1), Y is themeasure of response associatedwith
each factorial level combination; b0 is an intercept; bi is the
regression coefficient computed from observed experimental
values of Y; X1, X2, X3, and X4 stand for main effects of the
formulation variables; E stands for interaction between the
formulation variables like X1X3 and X2X4 etc; Curvature is the
quadratic termof the independent variables like (X1)
2 and (X2)
2
etc, which was used to simulate the curvature of the designed
sample space. In addition to regression analysis, a backward
elimination procedure was used to fit the obtained data to the
quadratic model.3. Results and discussion
3.1. Preliminary study
The preliminary study was conducted to evaluate the effect of
various formulation factors such as carvedilol loading, matrix
thickness, adhesive layer thickness, and propylene glycol
concentration on the release of carvedilol from the patches as
well as their permeation profile across an artificial membrane.
This study was conducted to evaluate one formulation vari-
able at a time. Thus, only one parameter was varied keeping
other parameters constant.
As outlined in Table 1, a total of 16 formulations (formu-
lations P1eP16) were investigated as the preliminary study.
The effect of four formulation variables studied on drug
release as well as permeation profile of carvedilol from
carvedilol-loaded transdermal systems is shown in Figs. 1 and
2. Furthermore, the carvedilol released at 7 h and 24 h as well
Table 3eComposition of formulations generated based onCentral Composite IVmodel and results of response parameters
obtained from in-vitro release as well as permeation profiles of respective formulation of transdermal systems.
Formulation
code
Formation variable Response parameter
Carvedilol
loading
(% w/w
of polymer)
HPMC
matrix
thickness
(mm)
Adhesive
layer
thickness
(mm)
Propylene
glycol
concentration
(% v/v of
solution)
Cumulative
carvedilol
released
at 7 h
(%  S.D.)
Cumulative
carvedilol
released
at 24 h
(%  S.D.)
Permeation
flux
(mg/cm2/h  S.D.)
Factorial points
F1 10 500 12.5 2 63.3  4.4 96.6  7.4 50.7  3.2
F2 10 500 37.5 5 23.2  1.9 38.2  2.8 10.6  0.9
F3 10 1100 12.5 5 78.8  5.3 99.2  8.9 70.3  6.2
F4 10 1100 37.5 2 21.0  1.0 29.6  1.3 5.2  0.2
F5 15 500 12.5 5 89.6  6.4 97.6  9.9 78.6  5.7
F6 15 500 37.5 2 22.3  1.4 33.0  3.0 6.6  0.3
F7 15 1100 12.5 2 69.6  4.4 96.4  6.8 50.9  4.1
F8 15 1100 37.5 5 25.1  1.5 45.2  2.8 11.1  0.9
Axial points
F9 7.5 800 25 3.5 36.8  1.4 69.1  3.9 13.6  1.0
F10 17.5 800 25 3.5 59.5  3.6 99.8  8.8 35.6  2.3
F11 12.5 200 25 3.5 56.2  2.5 98.0  7.8 24.0  2.5
F12 12.5 1400 25 3.5 39.7  1.4 78.3  5.3 20.1  1.5
F13 12.5 800 0 3.5 93.4  7.3 98.9  7.3 79.4  5.7
F14 12.5 800 50 3.5 18.9  0.9 25.5  2.5 3.5  1.4
F15 12.5 800 25 0.5 27.3  1.4 50.3  3.5 11.1  1.0
F16 12.5 800 25 6.4 73.4  4.3 100.6  8.4 61.4  2.7
Center points (replicates)
F17 12.5 800 25 3.5 47.6  3.2 96.1  5.0 25.6  1.4
F18 12.5 800 25 3.5 51.9  2.5 96.4  4.1 26.3  1.9
F19 12.5 800 25 3.5 51.3  3.0 98.4  3.2 24.7  1.7
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summarized in Table 1.
3.1.1. Effect of carvedilol loading
The effect of carvedilol loading on release of carvedilol from
patches is represented in Fig. 1A, which shows that the release
of carvedilol increasedwith increase in carvedilol loading. The
carvedilol released at 7 h increased from 21.9  0.8% (formu-
lation P1) to 53.4  3.2% (formulation P4). Similar results were
seen in carvedilol released at 24 h. Carvedilol release
increased from 32.7  2.4% (formulation P1) to 100.7  7.3%
(formulation P4). These results may be attributed to the
change in carvedilolepolymer ratio with a change in carve-
dilol loading. As the carvedilol loading is decreased, the
polymer fraction in the carvedilolepolymer ratio increases. It
stands to reason that higher percentage of polymer produces a
dense polymeric network upon hydration with water, which
will result in reduced diffusivity of carvedilol [8].
The permeation profiles of carvedilol across the artificial
membrane, resulting from the effect of carvedilol loading are
shown in Fig. 2A. The results obtained are in accordance with
those observed in the release study. The permeation flux of
carvedilol increased from 4.2  0.3 mg/cm2/h (formulation P1)
to 11.0  1.0 mg/cm2/h (formulation P2), 23.5  1.5 mg/cm2/h
(formulation P3), and 27.2  2.9 mg/cm2/h (formulation P4),
when carvedilol loading increased from 8% to 10%, 12.5%, and
15%, respectively. Thus, an increase in carvedilol loading in
the patches led to an increase in permeation flux. Similarresults were reported in a study where high skin permeation
of benztropine was obtained with a higher drug loading in
the patch formulations [9]. According to Fick’s law of diffu-
sion, the permeation of the drug is directly proportional to
the drug concentration gradient across the membrane. Since
sink condition was maintained in this study, the concentra-
tion of the drug on the donor side of the membrane deter-
mined the rate at which the drug diffused through the
membrane.
3.1.2. Effect of HPMC matrix thickness
The effect of matrix thickness on release of carvedilol from
the patches is displayed in Fig. 1B. The rate of release
decreased with an increase in the matrix thickness. The car-
vedilol released at 7 h decreased from 95.0 1.1% (formulation
P5, matrix thickness ¼ 400 mm) to 90.7  2.7% (formulation P6,
matrix thickness ¼ 800 mm) and 84.3  3.5% (formulation P7,
matrix thickness ¼ 1600 mm). This decrease appears to be due
to an increase in the diffusion path length that carvedilol had
to travel. Transdermal systems prepared solely with HPMC
films (without adhesive coating) exhibited burst release dur-
ing the first hour of the study and then plateaued. Almost 80%
of carvedilol loading was released during the initial 1e2 h
(Fig. 1B). Apparently the high hydrophilic character of HPMC
matrix (due to its composition i.e., HPMC and propylene gly-
col) accelerated matrix hydration and swelling leading to the
burst effect. This could further be explained by the drug
release mechanism suggested by Siepmann and Peppas.
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Fig. 1 e Effect of carvedilol loading (A), matrix thickness (B), adhesive layer thickness (C), and propylene glycol concentration
(D) on the in-vitro release of carvedilol from the patches (Data shown as mean ± standard deviation, n [ 3).
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 8e3 8 33According to the authors the following steps are involved in
the release of drug from the HPMC matrix: (i) water imbibes
into the matrix due to initially steep water concentration
gradient at polymer/water interface; (ii) this causes the HPMC
to swell, resulting in dramatic changes of polymer and drug
concentrations, which changes the dimensions of the system;
(iii) in the case of high initial drug loadings, the inner structure
of the matrix changes significantly during drug release,
becoming more porous and less restrictive for diffusion upon
drug depletion [10].
The effect of matrix thickness on the permeation profile of
carvedilol is shown in Fig. 2B. It was observed that permeation
flux value decreased from 115.5 9.3 mg/cm2/h to 45.1 5.0 mg/
cm2/h with an increase in matrix thickness from 400 mm to
1600 mm. These results are in accordance with the results
obtained for the same formulations in the release study.
3.1.3. Effect of adhesive layer thickness
A burst release of carvedilol from the patches was observed
when the carvedilol-loaded HPMC matrices were fabricated
without the incorporation of adhesive layer (formulations P5,
P6, and P7). The effect of adhesive layer on carvedilol release
from the patch formulations is shown in Fig. 1C. A 12.5 mmadhesive layer could control the burst release thereby
decreasing the carvedilol released at 7 h from 90.7  2.7%
(formulation P8, without adhesive layer) to 79.8  3.1%
(formulation P9, containing 12.5 mm thick adhesive layer). The
release was further controlled by increasing the adhesive
layer thickness to 25 mm (43.8  2.9% from formulation P10),
50 mm (19.8  % 0.9 from formulation P11), and 100 mm
(17.1  1.0% from formulation P12). Similarly, carvedilol
release decreased progressively from 98.8  3.0% (formulation
without adhesive layer) to 22.1 1.7% (formulation containing
100 mm thick adhesive layer). Evaluating carvedilol released at
the end of 24 h, it may be concluded that carvedilol release
from the patches decreased tremendously with increase in
thickness of adhesive layer. This could be attributed to the
higher solubility of carvedilol in the adhesive system which
reduces the thermodynamic activity of carvedilol in the
formulation, which in turn reduces the release of carvedilol
[11]. These results are in agreement with a study which
attempted to modulate drug release by various formulation
variables, the presence and type of adhesive being the main
variable [12]. From Fig. 1C, it can be seen that although the
initial burst release was efficiently controlled by a 12.5 mm
thick adhesive layer, it was not efficient to control the release
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Fig. 2 e Effect of carvedilol loading (A), matrix thickness (B), adhesive layer thickness (C), and propylene glycol concentration
(D) on the in-vitro permeation of carvedilol across artificial membrane (Data shown as mean ± standard deviation, n [ 3).
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 8e3 834up to 24 h which is required in this study. Thus, a 25 mm thick
adhesive layer would be optimum for this study.
Fig. 2C presents permeation profile of carvedilol for various
formulations containing different thicknesses of adhesive
layer. A significant decrease in permeation flux was observed
with an increase in adhesive layer thickness. The permeation
flux decreased from 53.9  4.2 mg/cm2/h from formulation
containing 12.5 mm thick adhesive layer (formulation P9) to
1.8  0.1 mg/cm2/h from formulation containing 100 mm thick
adhesive layer (formulation P12). The permeation of carvedilol
across the membrane appears to be strongly affected by the
thickness of adhesive layer, similar to the pattern observed in
the carvedilol release study.
3.1.4. Effect of propylene glycol concentration
Propylene glycol was used as a plasticizer to obtain uniform
films of HPMC as matrix type of transdermal system. The ef-
fect of propylene glycol on the release of carvedilol from the
patches is shown in Fig. 1D. Increase in propylene glycol
concentration increased the release of carvedilol from the
patches. This is evident from carvedilol released at 7 h as well
as at 24 h from formulations containing 1.5%, 2.5%, 3.5% or
4.5% propylene glycol. The results in Fig. 1D also indicate that4.5% of propylene glycol was not efficient in controlling the
release of carvedilol up to 24 h. On the other hand, 1.5% and
2.5% of propylene glycol controlled the release of the carve-
dilol to such an extent that less than 40% of the carvedilol
loading was released in 24 h. Thus, 3.5% concentration of
propylene glycol would be optimum for this study.
The increase in carvedilol release from the patches with
increase in the propylene glycol concentration could be
attributed to the high hydrophilic character of propylene
glycol which acts as a humectant and leads to more water
available in the patches to release carvedilol. A similar study
where propylene glycol was used along with HPMC reported
that the presence of propylene glycol led to high hydrophi-
licity of the matrix leading to higher rate of drug release [13].
The reason given for such observation was the formation of
hydrophilic micropores in the system aiding water uptake.
Other studies have also shown that propylene glycol along
with ethanol works as a better release and penetration
enhancer [14e19]. Thus, the presence of ethanol used in the
preparation of carvedilol solution and propylene glycol in the
adhesive layer exhibited synergistic effect.
The permeation of carvedilol across the membrane from
various formulations containing different concentrations of
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increase in propylene glycol concentration led to an increase
in permeation flux from 8.8  3.2 mg/cm2/h (formulation P13,
containing 1.5% propylene glycol) to 41.7  2.8 mg/cm2/h
(formulation P16, containing 4.5% propylene glycol). This is in
accordance with the results obtained in the release study. It
has been shown that propylene glycol acts as a release as well
as a penetration enhancer. Hence, propylene glycol alongwith
ethanol in the adhesive layer further enhanced these effects
[18]. The mechanism of permeation enhancing action of pro-
pylene glycol is almost similar to that suggested for ethanol.
Permeation of the solvent through the membrane could alter
thermodynamic activity of the drug in the vehicle which
would in turn modify the driving force for diffusion, and the
solvent may partition into the membrane facilitating the up-
take of the drug in the receptor solution across the membrane
[19,20].
In summary, the effect of four formulation variables on
carvedilol release during the preliminary study (shown in
Fig. 1) suggest the following: (i) The presence of adhesive layer
reduced the burst release of carvedilol leading to a better
controlled delivery of the carvedilol from the transdermal
systems. (ii) Adhesive layer appeared to play a dominating role
in controlling the rate of carvedilol release from the patches as
evidenced by the tremendous decrease in release rate of car-
vedilol with a nominal increase in the adhesive layer thick-
ness. (iii) The amount of carvedilol released from the
transdermal systems increased with an increase in carvedilol
loading and decreased with an increase in matrix thickness.
(iv) High carvedilol release could be achieved from the HPMC
matrix type of transdermal systems; however, HPMC being
very hydrophilic it also leads to burst release of the carvedilol.
(v) The propylene glycol used as a plasticizer for HPMCmatrix
also played a role in controlling carvedilol release from the
patches. The release rate of carvedilol from the patches
increased as the concentration of propylene glycol increased.
(vi) Similar results were obtainedwhen the effect of these four
formulation variables was studied on permeation profiles of
carvedilol through the artificial membrane, as shown in Fig. 2.3.2. Statistical optimization of the formulation variables
Based on the conclusions of the preliminary studies, further
evaluation of formulation variables was performed using the
principle of design of experiments to identify an optimal
combination of formulation variables for the fabrication of
patches having desired drug release rate and permeation flux.
As outlined in Table 3, a total of 19 formulations (formulations
F1eP16), conceived from the Central Composite IVmodel, was
studied. The results of drug release as well as permeation
profile of carvedilol from carvedilol-loaded transdermal sys-
tems are shown in Figs. 3e5. Fig. 3 shows the release and
permeation profiles of the 3 central points while Figs. 4 and 5
show the release and permeation profiles of the 8 factorial
design points and 8 axial points. Furthermore, the carvedilol
released at 7 h and 24 h as well as permeation flux, selected as
dependent variables to be used for the regression analysis to
identify the optimal formulation of carvedilol-loaded trans-
dermal system, are also summarized in Table 3.3.3. In-vitro drug release studies of carvedilol
Three replicates of the center point (formulations F17, F18 &
F19) of the Central Composite IV model were used to evaluate
the potential error resulting from experimental conditions
instead of formulation variables evaluated. This enables the
determination of lack of fit of the suggested regressionmodel.
Clustering and overlapping of results from release and
permeation profiles of carvedilol shown in Fig. 3 indicate that
the experimental error due to the procedure is within the
controllable range and the selection of the center point for the
experimental design is appropriate.
AsshowninFig.4,at theendof24h,almost100%ofcarvedilol
loadingwas released from formulations F1, F3, F5 & F7 (factorial
points containing 12.5 mm thick adhesive layer), and formula-
tions F10, F11, F13 & F16 (the axial point formulations). Formu-
lationF13showedaburst releaseof carvediloldue to theabsence
of adhesive layer. Formulation F5 gave the highest carvedilol
release rate, which could be attributed to the 12.5 mm thick
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thickness and high carvedilol loading. In contrast, formulation
F14showedthe lowest release ratemainlydue to the50mmthick
adhesive layer. In formulations F8 and F2, though the concen-
tration of propylene glycol was high, release rate of carvedilol
was very low mainly due to the thicker adhesive layer. Similar
results were obtained for formulation F6 which exhibited very
low release rate of carvedilol despite high carvedilol loading.
Thus, it may be concluded that the adhesive layer played a
dominating role in controlling release of carvedilol from the
formulation.
The response parameters obtained from the release pro-
files of carvedilol from patch formulations to be used for
regression analysis are given in Table 3. The values of carve-
dilol released at 7 h for formulations F2 (23.2  1.9%), F4
(21.0  1.0%), F6 (22.3  1.4%), and F8 (25.1  1.5%) were
observed to be lower than 30% of carvedilol loading mainly
due to the adhesive layer as discussed in the above paragraph.
The values of carvedilol released at 24 h indicate that less than
50% of carvedilol loading was released from the formulations
(formulations F2, F4, F6, F8) having high adhesive layer
thickness. Furthermore, burst release of carvedilol was seen in
formulation F13 (93.4  7.3% released at 7 h) indicating inef-
ficient control of carvedilol release up to 24 h due to the
absence of adhesive layer.3.4. In-vitro permeation studies of carvedilol
Permeation profiles of formulations from the Central Com-
posite IV model are shown in Fig. 5. The permeation flux was
calculated and the results are summarized in Table 3. Perme-
ation flux values greater than 50 mg/cm2/h were observed for
formulations F13 (79.4 5.7 mg/cm2/h), F5 (78.6 5.7 mg/cm2/h),
F3 (70.3  6.2 mg/cm2/h), F16 (61.4  2.7 mg/cm2/h), F7
(50.94.1mg/cm2/h), andF1 (50.73.2mg/cm2/h). Thismightbe
attributed to the high release rate of carvedilol seen for these
formulations and the presence of permeation enhancer/low
adhesive layer thickness in these formulations. This confirms
the fact that the presence of permeation enhancer and adhe-
sive layer is crucial in permeation of carvedilol to control drug
permeation across the membrane.3.5. Regression analysis of optimization of formulation
Based on the values of response parameters summarized in
Table 3, backward stepwise regression was performed to
generate regression equations for different response param-
eters. The results of the regression coefficients for each term
in the regression model together with the respective correla-
tion coefficient (r2) of the model are as follows:
For carvedilol released at 7 h (R7h), the quadratic equation
can be expressed as Equation (2):
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þ 188ðX4Þ2  626X1X2  318X1X3
þ 173X1X4

r2 ¼ 0:9970 (2)
For carvedilol released at 24 h (R24h), the quadratic equation
can be expressed as Equation (3):
R24h ¼ 776þ 260X1  152X2  1449X3 þ 566X4 þ 558ðX3Þ2
þ 153ðX4Þ2  501X1X2  254X1X3
þ 139X1X4

r2 ¼ 0:9980 (3)
For permeation flux of carvedilol, the quadratic equation
can be expressed as Equation (4):
Flux ¼ 4:21þ 0:60X1  2:97X3 þ 0:95X4
þ 0:44ðX3Þ2

r2 ¼ 0:9183 (4)
These three equations indicate the quantitative effect of
formulation variables (X1,X2,X3, andX4) and their interactions
on the responses R7h, R24h and permeation flux. The values ofthe coefficients of X1, X2, X3 and X4 are associated with the
effect of these variables on the response parameters. Co-
efficients with more than one factor represent an interaction
effect, whereas those with higher order terms denote
quadratic relationships. A positive sign signifies a synergistic
effect, whereas a negative sign stands for an antagonist effect.
Only the coefficients that were statistically significant
(P < 0.05) were retained in the equations. From all the
regression equations, it is seen that the regression coefficient
of ‘X3’ (the adhesive layer thickness) is larger than any other
regression coefficient, indicating that thickness of the adhe-
sive layer has dominating role in controlling carvedilol release
from the patches as well as permeation of carvedilol across
the membrane. This is due to the high lipophilicity of the
adhesive layer which reduces diffusivity of carvedilol thereby
decreasing the amount of carvedilol released. The values of
the coefficients of carvedilol loading and propylene glycol
concentration are in accordance with the results obtained in
the preliminary results i.e., increase in carvedilol loading and
increased propylene glycol concentration increase carvedilol
release aswell as permeation flux. The regression equation for
permeation flux also indicates that matrix thickness does not
have a significant effect on carvedilol permeated across the
membrane. According to the 3 regression equations, the r2
value is high indicating the adequacy of the quadratic model.
Since some of the response measurements were
competing with each other, a constrained optimization tech-
nique was used to generate the optimum setting for the final
formulation through proper interplay of different formulation
factors. Therefore, the following constraints were used to
optimize the formulation: (i) Minimization of the initial/burst
release, thus, a 40e45% carvedilol release in the initial 7 h
would be favorable. (ii) About 98e100% carvedilol release in
24 h so as to efficiently control the carvedilol release over 24 h.
(iii) A permeation flux value of 25 mg/cm2/h. Following the
treatment of the constrained optimization, using 47.9% of
carvedilol released at 7 h and 99.8% at 24 h as well as 25.7 mg/
cm2/h of permeation flux, a formulation having composition
of 12.5% carvedilol loading, 1000 mm matrix thickness, 25 mm
adhesive layer thickness, and 5%propylene glycol was devel-
oped as the optimal formulation of the patch. Excellent cor-
relations were obtained between the observed and predicted
values of drug release and permeation (Fig. 6). The results of
this regression analysis show that the quadratic mathemat-
ical model developed could be used to further predict formu-
lations with desirable release and permeation properties of
carvedilol from transdermal systems.4. Conclusion
The in-vitro drug release as well as permeation profiles of car-
vedilol from transdermal systems were found to be greatly
influenced by the formulation variables such as carvedilol
loading, matrix thickness, adhesive layer thickness, and pro-
pylene glycol concentration and these variables could be suit-
ably altered to achieve the desired controlled release profile of
carvedilol. Statistical optimization proved to be very useful in
the subsequent formulation development work following pre-
liminary evaluations. The optimizationwork consisted of three
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 2 8e3 838major parts, narrowing down the formulation variables,
generating optimized formulations using Central Composite IV
design and optimizing the final formulation using constrained
optimization. Thus, the design of experiment with response
surface method is an efficient tool to determine and optimize
formulation conditions within experimental conditions. Over-
all, an optimized carvedilol-loaded transdermal system was
successfully developed which could control the release as well
as permeation of carvedilol up to 24 h.Acknowledgments
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